PTCT:NSD-PTC Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 45.35

Change

-0.21 (-0.46)%

Market Cap

USD 3.75B

Volume

0.19M

Analyst Target

USD 60.30
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+2.91 (+0.72%)

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

-0.66 (-0.09%)

USD 84.94B
ARGX argenx NV ADR

+1.67 (+0.27%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

+0.99 (+0.41%)

USD 31.66B
BGNE BeiGene Ltd

+3.92 (+2.21%)

USD 20.24B
UTHR United Therapeutics Corporatio..

-2.78 (-0.76%)

USD 16.18B
MRNA Moderna Inc

+0.68 (+1.72%)

USD 16.10B
RPRX Royalty Pharma Plc

-0.02 (-0.08%)

USD 15.27B
SMMT Summit Therapeutics PLC

+0.33 (+1.77%)

USD 13.67B
INCY Incyte Corporation

+0.07 (+0.10%)

USD 13.52B

ETFs Containing PTCT

MSGR 6.14 % 0.00 %

N/A

N/A
IBRN iShares Trust - iShares N.. 6.05 % 0.00 %

+0.02 (+0%)

USD 3.86M
SBIO ALPS Medical Breakthrough.. 2.63 % 0.50 %

-0.04 (0%)

USD 0.11B
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

+0.10 (+0%)

N/A
BIOT 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 64.55% 86% B+ 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 64.55% 86% B+ 89% A-
Trailing 12 Months  
Capital Gain 59.18% 85% B 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.18% 85% B 88% B+
Trailing 5 Years  
Capital Gain -7.32% 74% C 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.32% 74% C 40% F
Average Annual (5 Year Horizon)  
Capital Gain -4.16% 41% F 28% F
Dividend Return -4.16% 40% F 27% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 36.85% 77% C+ 52% F
Risk Adjusted Return -11.28% 36% F 28% F
Market Capitalization 3.75B 93% A 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector